tbuckley/cabot-search huggingface dataset:
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positive and negative
Authors: S. Lee, M-C. Lim, Y.M. Kim, J.H. No, B-G. Kim, C.H. Cho, None S.H. Kim, D.H. Jeong, J-K. Lee, J.S. Park, Y-J. Choi, K.O. Jeon, J.W. Woo, Y.C. Sung, S. Hur
Journal: Annals of Oncology (2022)
LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
Authors: C. Pinto, A. Orlandi, N. Normanno, E. Maiello, M.A. Calegari, L. Antonuzzo, R. Bordonaro, M.G. Zampino, S. Pini, F. Bergamo, G. Tonini, A. Avallone, T.P. Latiano, G. Rosati, A. Pazzola, A. Ballestrero, A. Zaniboni, M. Roselli, S. Tamberi, C.A. Barone
Journal: Annals of Oncology (2022)
LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
Authors: O. Gluz, U.A. Nitz, M. Christgen, S. Kuemmel, M. Braun, M. Thill, B. Aktas, P. Wimberger, K. Luedtke-Heckenkamp, M. Zaiss, M. Warm, C. Schumacher, C. Schem, M. Graeser, A.D. Hartkopf, R.E. Kates, C. zu Eulenburg, P. Schmid, H. Kreipe, N. Harbeck
Journal: Annals of Oncology (2022)
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Authors: S. Qin, M. Kudo, T. Meyer, R.S. Finn, A. Vogel, Y. Bai, Y. Guo, Z. Meng, T. Zhang, T. Satoh, A. Hiraoka, D. Marino, E. Assenat, L. Wyrwicz, M. Calvo Campos, K. Hsing-Tao, F. Boisserie, S. Li, Y. Chen, A.X. Zhu
Journal: Annals of Oncology (2022)
LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Authors: S. Patel, M. Othus, V. Prieto, M. Lowe, E. Buchbinder, Y. Chen, J. Hyngstrom, C.D. Lao, T-G. Truong, S. Chandra, K. Kendra, C. Devoe, A. Hedge, A. Mangla, E. Sharon, L. Korde, J. Moon, V. Sondak, A. Ribas
Journal: Annals of Oncology (2022)
LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Authors: A. Hollebecque, M. Borad, L. Goyal, A. Schram, J.O. Park, P.A. Cassier, S.D. Kamath, D.T. Wai Meng, E. Dotan, R. Kim, V. Sahai, D-Y. Oh, C-Y. Liao, M. Millward, D. Roda Perez, C. Ferté, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley
Journal: Annals of Oncology (2022)
1628TiP Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in solid tumors: Two phase III, international, randomized controlled trials (RCT)
Authors: H. Al-Samkari, C. Geredeli, C. Arslan, I. Korantzis, G.G. Dogu, M. Nechaeva, M. Salgado Fernandez, B. Gonzalez Astorga, V.I. Yordanov, T-E. Ciuleanu, C. Bowers, A. Armas, F. Scotté, J.F.C. Camargo, C.G. Munoz Sanchez-Miguel, P.A. Bunn, D. Kuter, G.A. Soff
Journal: Annals of Oncology (2022)
1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)
Authors: A. Sacher, S. Lau, M. Allen, L. Corke, M. Makarem, E. Chen, R.W-J. Jang, E. Elimova, R. Grant, F.A. Shepherd, P. Bradbury, L. Eng, P. Rogalla, G. Liu, M-S. Tsao, N. Leighl, R. Garonce-Hediger, B. Wang, P. Ohashi, J. Knox
Journal: Annals of Oncology (2022)
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
Authors: J-P. Machiels, Y. Tao, B. Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P.F. Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, S. Laban, R. Greil, M. Burian, M. Hetnal, L.F. Licitra, R. Swaby, Y. Zhang, B. Gumuscu, B. Bidadi, L.L. Siu
Journal: Annals of Oncology (2022)
LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
Authors: B. Xu, M. Yan, F. Ma, W. Li, Q. Ouyang, Z. Tong, Y. Teng, S. Wang, Y. Wang, C. Geng, T. Luo, J. Zhong, Q. Zhang, Q. Liu, X. Zeng, T. Sun, Q. Mo, F. Dong, S. Wu, X. Zhu
Journal: Annals of Oncology (2022)
LBA31 Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
Authors: K. Fujiwara, S. Nishio, K. Yamamoto, H. Fujiwara, H. Itagaki, T. Nagai, H. Takano, S. Yamaguchi, A. Kudoh, Y. Suzuki, T. Nakamoto, M. Kamio, K. Kato, K. Nakamura, K. Takehara, H. Yahata, H. Kobayashi, M. Saito, K. Ushijima, K. Hasegawa
Journal: Annals of Oncology (2022)
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)
Authors: M.H.H. Schuler, K. Cuppens, T. Ploenes, M. Vanbockrijck, M. Wiesweg, K. Darwiche, A. Schramm, B. Maes, B. Hegedus, H-U. Schildhaus, H. Hautzel, D. Theegarten, P. Baas, K. Hartemink, B. Du Pont, C. Aigner
Journal: Annals of Oncology (2022)
LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
Authors: J. Tabernero, T. Yoshino, T.W. Kim, R. Yaeger, J. Desai, H.S. Wasan, E. Van Cutsem, F. Ciardiello, T. Maughan, C. Eng, J. Tie, M.E. Elez Fernandez, S. Lonardi, X. Zhang, R. Chavira, T. Usari, E. Hahn, S. Kopetz
Journal: Annals of Oncology (2022)
LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial
Authors: C. Lepage, J.M. Phelip, L. Cany, E. Barbier, S. Manfredi, P. Deguiral, R. Faroux, M. Baconnier, D. Pezet, E. Terrebonne, A. Adenis, M. Ben Abdelghani, J.F. Ain, G. Breysacher, I. Boillot Benedetto, A. Pelaquier, A. Lievre, P. Laurent Puig, F. Bibeau, O. Bouche
Journal: Annals of Oncology (2022)
LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
Authors: I. Nederlof, O.I. Isaeva, N. Bakker, M. de Graaf, R.F. Salgado, N. Klioueva, K. Van De Vijver, F. van Duijnhoven, E. Kalashnikova, S. Willingham, S. Luykx, C.E. Loo, E. Kerver, G.S. Sonke, C.U. Blank, R. Mann, S.C. Linn, D. Lambrechts, H. Horlings, M. Kok
Journal: Annals of Oncology (2022)
LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma
Authors: S. Kim, E. Wuthrick, D.M. Blakaj, Z. Eroglu, C. Verschraegen, R. Thapa, M. Mills, K. Dibs, C. LIveringhouse, J. Russell, J. Caudell, A. Tarhini, J. Markowitz, D-T. Chen, T. Rose, J. Messina, V. Sondak, K. Tsai, N.I. Khushalani, A. Brohl
Journal: Annals of Oncology (2022)
LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
Authors: J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin, I. Tsibulak, D. Cibula, I.B. Vergote, O.S. Rosengarten, M.J. Rodrigues, N. de Gregorio, J. Martinez-Garcia, P. Pautier, M.A. Mouret Reynier, F. Selle, V. D'Hondt, F. Joly Lobbedez, E. Bultot Boissier, A. Floquet, P-E. Heudel, F. Heitz
Journal: Annals of Oncology (2022)
1778P Comparative genomic alterations (GA) landscape in urothelial carcinoma of the bladder (UCB) in patients of South Asian ancestry (SAS)
Authors: P.E. Spiess, G. Bratslavsky, P. Grivas, J. Jacob, A. Necchi, N.A. Danziger, D.C. Pavlick, H. Tukachinsky, R.P. Graf, J.S. Ross
Journal: Annals of Oncology (2022)
LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Authors: M.J.G. Bond, K. Bolhuis, O.J.L. Loosveld, H.J. Droogendijk, J.W.B. de Groot, M.P. Hendriks, B. De Valk, M.S.L. Liem, A.M. Rijken, K. Verhoef, J.H.W. de Wilt, K.P. de Jong, G. Kazemier, M.J. van Amerongen, M.R.W. Engelbrecht, J.M. Klaase, A. Komurcu, M.I. Lopez-Yurda, R-J. Swijnenburg, C.J.A. Punt
Journal: Annals of Oncology (2022)
LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC
Authors: J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, A.S. Paulson, J. Hubbard, A. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, D.L. Bajor, M. Stecher, W. Feng, T. Bekaii-Saab
Journal: Annals of Oncology (2022)
LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
Authors: S.J. Klempner, J. Weiss, M. Pelster, A. Spira, M. Barve, S-H.I. Ou, T.A. Leal, T. Bekaii-Saab, J.G. Christensen, T. Kheoh, K. Velastegui, H. Der Torossian, R. Yaeger
Journal: Annals of Oncology (2022)
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study
Authors: P. Grivas, P.K. Agarwal, H. Al-Ahmadie, T. Friedlander, D. Geynisman, I. Hussain, Y. Lotan, A.K. Morgans, M. Tesic-Schnell, J. Meeks
Journal: Annals of Oncology (2022)
1773P Prediction of neoadjuvant chemotherapy response in muscle-invasive bladder cancer: A machine learning approach
Authors: E. Shkolyar, H. Bhambhvani, E. Tiu, V. Krishna, V. Krishna, V. Nimgaonkar, R. Krishnan, O. O'Donoghue, D. Vrabac, C-S. Kao, A. Joshi, J. Shah
Journal: Annals of Oncology (2022)
LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
Authors: F. André, J.C. Nadal, H. Denys, S. Goel, L.M. Litchfield, A. Appiah, Y. Chen, S.M. Tolaney
Journal: Annals of Oncology (2022)
Stroke family care workers
Authors: A. F Bisset, R. Chesson, P. Pound, P. Gompertz, S. Ebrahim, M A Chamberlain, J M L Geddes, A. Wasti, R. Trigg, V. Wood, M. Dennis, C. Warlow, S. O'Rourke
Journal: BMJ (1997)

Study in Lothian confirms findings
Highlights from Recent Cancer Literature
Journal: Cancer Research (2013)

Despite advances in therapeutic targeting, most drugs still have unwanted side effects.A new study by Knight and colleagues illustrates a potential beneficial side effect of BRAF inhibitors, an increase in theT-cell ratio.The authors suggest that augmenting this effect may lead to an increased antitumor efficacy of BRAF inhibitors.The initial observation that BRAF inhibitors may alter host immunity came from Wilmott and colleagues, who analyzed patient biopsies, demonstrating increased CD8 þ T-cell infiltrates in tumors treated with a BRAF inhibitor.Following up on this observation, Knight and colleagues used a syngeneic model of Braf V600E -driven melanoma that has an intermediate sensitivity to BRAF inhibition.Through a series of experiments, they show that in their model the antitumor efficacy of BRAF inhibition is partially dependent on a drug-induced decrease in expression of tumorderived CCL2.Importantly, it is the expression of CCR2, the receptor for CCL2, on nonneoplastic, host-derived cells that is critical for this antitumor efficacy.These authors go on to show that CCR2 is expressed on Foxp3 þ CD4 þ tumor-infiltrating T cells and upon treatment they see a relative decrease in Foxp3 þ CD4 þ tumorinfiltrating lymphocytes and a modest increase in NK1.1 þ (KLRB1C) NK cells and CD8 þ T cells.Using monoclonal antibodies to modulate the immune response and mice with knockout of specific immune cell subsets, Knight and colleagues show that the antitumor effect of the BRAF inhibitor is dependent on functional CD8 þ T cells.They suggest that future clinical trials should test the antitumor efficacy of combining BRAF inhibitors with immunotherapy, and in support of this approach, they demonstrate a synergistic antitumor activity in both mouse transplant and de novo tumorigenesis models treated with a combination of BRAF inhibition and anti-CD137 (TNFRSF9) antibody.(Image from
Speculation on Future Use of Blood or Blood Component Therapy
Authors: Israel Davidsohn
Journal: JAMA (1967)

In<i>The American College Dictionary</i>there are six definitions of "speculation." According to the one best applicable to our topic, "speculation" means conjectural consideration of a matter. "Conjecture" is defined as expression of an opinion without sufficient evidence for proof. If I add to this definition the circumstance that the subject of this communication was assigned to me, then I could permit my imagination to roam as freely as that of a science-fiction writer and not be shackled by lack of supporting facts or by my own ignorance—of which, in this particular assignment, I have an abundant supply. However, tempted as I am, it is impossible to speculate so freely within the available space. This limitation and a respect for my audience have made me choose another approach, namely, the projecting into the future of the early attempts at blood therapy, even though these attempts have been, at least for
Dermatitis Herpetiformis.
Authors: John Montgomery Yost, Christopher S Hale, Shane A Meehan, Beth N McLellan
Journal: Annals of Internal Medicine (1977)

Dermatitis herpetiformis (DH) is an autoimmune bullous disease, which represents the cutaneous manifestation of gluten sensitivity, in the setting of celiac disease. Although classical DH is characterized clinically by grouped, vesicles on an erythematous base, primary lesions often are absent owing to the intense, associated pruritus. Instead, many cases present only with erythematous erosions with numerous overlying excoriations. As in celiac disease, the core pathogenic mechanisms of DH are likely mediated by immunoglobulin A class autoantibodies against one of several transglutaminase enzymes. As the production of these autoantibodies is directly correlated with gastrointestinal exposure to gliadin, which is an alcohol-soluble fraction of gluten, a gluten-free diet represents the cornerstone of a DH management regimen. In cases refractory to dietary management alone, dapsone is the first-line agent for the treatment of DH, although many other agents have been anecdotally reported as effective.
Biofilm-based delivery approaches and specific enrichment strategies of probiotics in the human gut
Authors: Jie Gao, Faizan Ahmed Sadiq, Yixin Zheng, Jinrong Zhao, Guoqing He, Yaxin Sang
Journal: Gut Microbes (2022)

The use of probiotics has been one of the effective strategies to restructure perturbed human gut microbiota following a disease or metabolic disorder. One of the biggest challenges associated with the use of probiotic-based gut modulation strategies is to keep the probiotic cells viable and stable during the gastrointestinal transit. Biofilm-based probiotics delivery approaches have emerged as fascinating modes of probiotic delivery in which probiotics show significantly greater tolerance and biotherapeutic potential, and interestingly probiotic biofilms can be developed on food-grade surfaces too, which is ideal for the growth and proliferation of bacterial cells for incorporation into food matrices. In addition, biofilms can be further encapsulated with food-grade materials or with bacterial self-produced biofilms. This review presents a newly emerging and unprecedently discussed techniques for the safe delivery of probiotics based on biofilms and further discusses newly emerging prebiotic materials which target specific gut microbiota groups for growth and proliferation.
Epigenetic master regulators HDAC1 and HDAC5 control pathobiont Enterobacteria colonization in ileal mucosa of Crohn’s disease patients
Authors: Mélissa Chervy, Adeline Sivignon, Flavie Dambrine, Anthony Buisson, Pierre Sauvanet, Catherine Godfraind, Matthieu Allez, Lionel Le Bourhis, None The Remind Group, Nicolas Barnich, Jérémy Denizot
Journal: Gut Microbes (2022)

Adherent-invasive Escherichia coli (AIEC), which abnormally colonize the ileal mucosa of Crohn's disease (CD) patients, are known to contribute to the etiopathogenesis of CD. Molecular mechanisms favoring AIEC ileal colonization have not been completely characterized yet. The aim of this study was to investigate whether epigenetic regulators histone deacetylases (HDAC) expression in intestinal epithelial cells of CD patients regulate Enterobacteria and AIEC encroachment to intestinal mucosa. HDAC were inhibited in vitro and in CEABAC10 mice to decipher their involvement in the entry of AIEC within host cells. CD ileal samples from the REMIND cohort were used to study the relationship between HDAC expression level and Enterobacteria/AIEC colonization in patients. Mice were fed a westernized diet and orally challenged with AIEC to determine the impact of diet on HDAC expression. Global level of acetylated histone H3 is higher in patients colonized by AIEC bacteria compared to patients non-colonized by Enterobacteria and HDAC inhibition-mediated H3 hyperacetylation promotes the entry of AIEC bacteria within intestinal epithelial cells. HDAC1 and HDAC5 are central and antagonistic in the regulation of AIEC entry within host cells in vitro, in mouse models and in ileal mucosa of CD patients. In mice fed a western-type diet, AIEC infection decreases HDAC1 expression, inducing H3 hyperacetylation to favor their own colonization. CD patients under a western diet are more prone to be colonized by AIEC bacteria as such a diet affects intestinal homeostasis, enables AIEC access to intestinal mucosa where they then manipulate host-epigenome to their advantage.Abbreviations AIEC Adherent-Invasive Escherichia coli; BSA Bovine serum albumin; CD Crohn's disease; CEABAC10 Carcinoembryonic antigen bacterial artificial chromosome 10; CEACAM Carcinoembryonic antigen-related cell adhesion molecule; FBS Fetal bovine serum; IBD Inflammatory Bowel Disease; HAT Histone acetyltransferase; HDAC Histone deacetylase; kDa KiloDalton; SAHA Suberoylanilide Hydroxamic Acid; Scr Scramble
Extracellular vesicle miRNAs promote the intestinal microenvironment by interacting with microbes in colitis
Authors: Qichen Shen, Zhuizui Huang, Lingyan Ma, Jiachen Yao, Ting Luo, Yao Zhao, Yingping Xiao, Yuanxiang Jin
Journal: Gut Microbes (2022)

Inflammatory bowel disease (IBD) is a global disease with no cure. Disruption of the microbial ecosystem is considered to be an important cause of IBD. Extracellular vesicles (EVs) are vital participants in cell–cell and cell-organism communication. Both host-derived EVs and bacteria-derived membrane vesicles (OMVs) contribute to homeostasis in the intestine. However, the roles of EVs-miRNAs and MVs in host-microbe interactions in colitis remain unclear. In the present study, the animal model of colitis was established by dextran sulfate sodium (DSS) to investigate the changes of miRNAs in colonic EVs from colitis. Several miRNAs were significantly altered in colitis EVs. miR-181b-5p transplantation inhibited M1 macrophage polarization and promoted M2 polarization to reduce the levels of inflammation both in acute and remission of chronic colitis. miR-200b-3p could interact with bacteria and regulate the composition of the microbiota, which contributed to intestinal barrier integrity and homeostasis. Notably, MVs from normal feces could effectively reverse the composition of the intestinal microbiota, restore the intestinal barrier and rescue colitis, and BMVs from colitis would also have similar effects after miR-200b-3p treatment. Our results preliminarily identify a vesicle-based host‐microbe interaction cycle in colitis and provide new ideas for colitis treatment.
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study
Authors: Dunya Tomic, Jedidiah I Morton, Lei Chen, Agus Salim, Edward W Gregg, Meda E Pavkov, Martti Arffman, Ran Balicer, Marta Baviera, Elise Boersma-van Dam, Ralph Brinks, Bendix Carstensen, Juliana C N Chan, Yiling J Cheng, Sandrine Fosse-Edorh, Sonsoles Fuentes, Hélène Gardiner, Hanne L Gulseth, Romualdas Gurevicius, Kyoung Hwa Ha, Annika Hoyer, György Jermendy, Alexandra Kautzky-Willer, Ilmo Keskimäki, Dae Jung Kim, Zoltán Kiss, Peter Klimek, Maya Leventer-Roberts, Chun-Yi Lin, Paz Lopez-Doriga Ruiz, Andrea O Y Luk, Stefan Ma, Manel Mata-Cases, Dídac Mauricio, Stuart McGurnaghan, Tomoaki Imamura, Sanjoy K Paul, Anna Peeters, Santa Pildava, Avi Porath, Cynthia Robitaille, Maria Carla Roncaglioni, Takehiro Sugiyama, Kang-Ling Wang, Sarah H Wild, Naama Yekutiel, Jonathan E Shaw, Dianna J Magliano
Journal: The Lancet Diabetes & Endocrinology (2022)
Pulmonary Embolus and Hemoptysis Revealing Rare Intralobar Sequestration
Authors: Niamh Boyle, Darragh K. Waters, Jeff McCann, Marcus Butler, Jonathan D. Dodd, Cormac McCarthy
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Pulmonary Embolus and Hemoptysis Revealing Rare Intralobar Sequestration." American Journal of Respiratory and Critical Care Medicine, 207(3), pp. e4–e5
Pulmonary Alveolar Microlithiasis in a Patient with Ellis–van Creveld Syndrome
Authors: Cheng Lei, Binyi Yang, Yan Zhang, Hong Luo
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Pulmonary Alveolar Microlithiasis in a Patient with Ellis–van Creveld Syndrome." American Journal of Respiratory and Critical Care Medicine, 207(5), pp. e29–e30